

**Tchaikapharma High Quality Medicines Inc.**  
**Interim statement of Financial status**  
**as of 31 of December 2025**

	<b>31.12.2025</b>	<b>31.12.2024</b>
	<b>BGN'000</b>	<b>BGN'000</b>
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment	33 534	33 304
Intangible assets	3 576	2 836
Investments in subsidiaries	69	69
Trade receivables	5 091	5 403
<b>Total non-current assets</b>	<b>42 270</b>	<b>41 612</b>
<b>Current assets</b>		
Inventories	17 925	15 862
Trade and other receivables	79 183	70 822
Current corporate income tax	-	129
Cash and cash equivalents	1 128	79
<b>Total current assets</b>	<b>98 236</b>	<b>86 892</b>
<b>Total assets</b>	<b>140 506</b>	<b>128 504</b>
<b>LIABILITIES</b>		
<b>Equity</b>		
Share capital	95 900	91 800
Reserves	13 549	13 147
Retained earnings	6 431	4 552
<b>Total</b>	<b>115 880</b>	<b>109 449</b>
<b>Non-current liabilities</b>		
Long-term loans	1 543	675
Deferred tax liabilities	1 198	1 198
Retirement benefit obligations	268	268
<b>Total non-current liabilities</b>	<b>3 009</b>	<b>2 141</b>
<b>Current liabilities</b>		
Trade and other liabilities	10 450	6 337
Short-term loans	9 284	9 784
Current portion of long-term loans	932	670
Other tax liabilities	951	123
<b>Total current liabilities</b>	<b>21 617</b>	<b>16 914</b>
<b>Total liabilities</b>	<b>24 626</b>	<b>19 055</b>
<b>Total equity and liabilities</b>	<b>140 506</b>	<b>128 504</b>

Date of preparation: 22.01.2026  
Sofia

Prepared by:.....  
/Ts. Pandeva/

Executive Director:.....  
/B. Georgiev/

**Tchaikapharma High Quality Medicines Inc.**  
**Interim statement of comprehensive income**  
**as of 31 of December 2025**


	<b>31.12.2025</b> <i>BGN'000</i>	<b>31.12.2024</b> <i>BGN'000</i>
Revenue	63 994	53 141
Other income	49	231
<b>Total income</b>	<b>64 043</b>	<b>53 372</b>
Carrying amount of goods sold	(3 249)	(2 251)
Changes in inventories of finished products and work in progress	666	(77)
Materials and services	(40 249)	(33 344)
Personnel expenses	(10 618)	(9 378)
Depreciation / amortisation expenses	(2 889)	(2 519)
Other expenses	(715)	(533)
Finance income	670	530
Finance costs	(568)	(768)
<b>Total expenses</b>	<b>(56 952)</b>	<b>(48 340)</b>
<b>Profit before taxation</b>	<b>7 091</b>	<b>5 032</b>
Corporate income tax expense	(660)	(540)
<b>Profit/Loss for the period</b>	<b>6 431</b>	<b>4 492</b>
	(50)	
<b>Total comprehensive income for the period</b>	<b>6 431</b>	<b>4 442</b>
Earnings per share / in BGN per 1 share /	0.07	0.05

Date of preparation: 22.01.2026

Sofia



Prepared by:.....  
/Ts. Pandeva/



Executive Director:.....  
/B. Georgiev/

**Tchaikapharma High Quality Medicines Inc.**  
**Interim cash flow statement**  
**as of 31 of December 2025**


	<b>31.12.2025</b> <i>BGN'000</i>	<b>31.12.2024</b> <i>BGN'000</i>
<b>Cash flows from operating activities</b>		
Proceeds from sale of finished products, goods and services	46 777	40 546
Payments to suppliers of materials, goods and services	(23 649)	(20 986)
Payments to personnel	(10 714)	(9 193)
Foreign currency exchange gains/losses	(29)	(48)
Payments of interest and dividends	(531)	(573)
<u>Other proceeds / payments</u>	<u>(8 275)</u>	<u>(6 381)</u>
<b><i>Net cash flows</i></b>	<b>3 579</b>	<b>3 365</b>
<b>Cash flows from investing activities</b>		
Payments on non-current assets acquired	(1 100)	(2 168)
<u>Other post/payments for investment activity</u>	<u>(50)</u>	
<b><i>Net cash flows</i></b>	<b>(1 100)</b>	<b>(2 218)</b>
<b>Cash flows from financial activities</b>		
Proceeds from loans	2 402	592
Payments on loans	(2 888)	(597)
Payment of interest, dividends	(421)	(601)
Payments on finance lease	(523)	(522)
<b><i>Net cash flows</i></b>	<b>(1 430)</b>	<b>(1 128)</b>
<b>Change in cash and cash equivalents</b>	<b>1 049</b>	<b>19</b>
Cash and cash equivalents at the beginning of the period	79	60
<b>Cash and cash equivalents at the end of the period</b>	<b>1 128</b>	<b>79</b>

Date of preparation: 22.01.2026

Sofia

Prepared by: .....  


/Ts. Pandeva/

Executive  
Director: .....  
  
/B. Georgiev /

**Tchaikapharma High Quality Medicines Inc.**  
**Interim statement on changes in equity**  
**as of 31 of December 2025**

	Registered (share) capital <i>BGN'000</i>	Revaluation reserves <i>BGN'000</i>	Other reserves <i>BGN'000</i>	Retained earnings / loss <i>BGN'000</i>	Total equity <i>BGN'000</i>
<b>Balance as of 01.01.2024</b>	<b>84 500</b>	<b>4 369</b>	<b>8 431</b>	<b>7 707</b>	<b>105 007</b>
Profit/loss for the period				4 492	4 492
Other comprehensive income			(50)		(50)
Including from tax effect of the revaluation of property, plant and equipment					
<b>Total comprehensive income</b>			<b>(50)</b>	<b>4 492</b>	<b>4 442</b>
Issue of shares by the owners	7 300		347		(7 647)
Dividends accrued					
Tantiennes accrued					
Profit transferred to reserves					
<b>Total amount of income and expenses recognised during the period</b>	<b>7 300</b>		<b>347</b>		<b>(7 647)</b>
<b>Balance as of 31.12.2024</b>	<b>91 800</b>	<b>4 319</b>	<b>8 778</b>	<b>4 552</b>	<b>109 449</b>
<b>Balance as of 01.01.2025</b>	<b>91 800</b>	<b>4 319</b>	<b>8 778</b>	<b>4 552</b>	<b>109 449</b>
Profit/loss for the period				6 431	6 431
Other comprehensive income					
<b>Total comprehensive income</b>				<b>6 431</b>	<b>6 431</b>
Issue of shares by the owners	4 100		452		(4 552)
<b>Total amount of income and expenses recognised during the period</b>					
<b>Balance as of 31.12.2025</b>	<b>95 900</b>	<b>4 319</b>	<b>9 230</b>	<b>6 431</b>	<b>115 880</b>

Date of preparation: 22.01.2026  
Sofia

Prepared by:.....  
/Ts. Pandeva/

Executive Director:.....  
/B. Georgiev/